News & Updates

New drug applications approved by US FDA as of 16 - 31 August 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The use of estrogen replacement therapy appears to yield a risk-lowering effect on gastric and colorectal cancers, as reported in a retrospective study.

Several adult patients with eosinophilic esophagitis (EoE) poorly adhere to their maintenance treatment, a recent study has found.

Patients with chronic kidney disease (CKD) can safely use synbiotics to reduce their levels of uraemic toxins and minimize microinflammation, reports a new study.

The presence of autoantibodies against the granulocyte macrophage-colony stimulating factor (aGMAb) appears to precede Crohn’s disease (CD) diagnosis by years, according to a recent study. AGMAbs could be used for the prediction of complicated CD.

The combination of nivolumab 1 mg/kg (NIVO1) and ipilimumab 3 mg/kg (IPI3) every 3 weeks followed by NIVO 240 mg every 2 weeks in the second-line setting continues to confer durable response and overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (aHCC), according to 5-year data from the CheckMate 040* trial presented at ESMO GI 2022.